<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Tendijck GAH</submitter><funding>ZonMw</funding><funding>Zorginstituut Nederland</funding><pagination>e105053</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12587972</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(11)</volume><pubmed_abstract>&lt;h4>Introduction&lt;/h4>In the Netherlands, approximately 2200 major amputations of the lower extremities are performed each year, the majority in vascular patients. Around 61% of these patients will develop postamputation pain (PAP). PAP is a severe, lifelong, disabling condition profoundly affecting quality of life. During amputations, the common practice is to cut the nerves without employing nerve-surgical techniques to prevent chronic pain due to neuroma formation. In recent years, targeted muscle reinnervation (TMR) has been the most frequently studied technique for treating PAP, inhibiting neuroma formation by rerouting the cut mixed nerve to a functional motor nerve. We hypothesise that a primary TMR procedure during major lower limb amputations will result in a lower prevalence of PA</pubmed_abstract><journal>BMJ open</journal><pubmed_title>Prevention of postamputation pain with targeted muscle reinnervation (PreventPAP trial): protocol for a national, multicentre, randomised, sham-controlled trial.</pubmed_title><pmcid>PMC12587972</pmcid><funding_grant_id>2023039665</funding_grant_id><pubmed_authors>Verduijn PS</pubmed_authors><pubmed_authors>Niesters M</pubmed_authors><pubmed_authors>Jong T</pubmed_authors><pubmed_authors>Malessy MJA</pubmed_authors><pubmed_authors>Steenhoven TJV</pubmed_authors><pubmed_authors>van den Hout WB</pubmed_authors><pubmed_authors>de Ruiter GCW</pubmed_authors><pubmed_authors>Pondaag W</pubmed_authors><pubmed_authors>PreventPAP consortium</pubmed_authors><pubmed_authors>Ploeg AJ</pubmed_authors><pubmed_authors>Zuidam JM</pubmed_authors><pubmed_authors>van Zwet EW</pubmed_authors><pubmed_authors>van de Water W</pubmed_authors><pubmed_authors>Rijken B</pubmed_authors><pubmed_authors>Duraku LS</pubmed_authors><pubmed_authors>van Schaik J</pubmed_authors><pubmed_authors>Kwee E</pubmed_authors><pubmed_authors>Mees BME</pubmed_authors><pubmed_authors>Wijk MPV</pubmed_authors><pubmed_authors>van Rijt WG</pubmed_authors><pubmed_authors>Groen JL</pubmed_authors><pubmed_authors>Jongkind V</pubmed_authors><pubmed_authors>Coert JH</pubmed_authors><pubmed_authors>van der Krogt H</pubmed_authors><pubmed_authors>Dijkman RR</pubmed_authors><pubmed_authors>Overgoor MLE</pubmed_authors><pubmed_authors>Yeung KK</pubmed_authors><pubmed_authors>Brakkee EM</pubmed_authors><pubmed_authors>Tendijck GAH</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prevention of postamputation pain with targeted muscle reinnervation (PreventPAP trial): protocol for a national, multicentre, randomised, sham-controlled trial.</name><description>&lt;h4>Introduction&lt;/h4>In the Netherlands, approximately 2200 major amputations of the lower extremities are performed each year, the majority in vascular patients. Around 61% of these patients will develop postamputation pain (PAP). PAP is a severe, lifelong, disabling condition profoundly affecting quality of life. During amputations, the common practice is to cut the nerves without employing nerve-surgical techniques to prevent chronic pain due to neuroma formation. In recent years, targeted muscle reinnervation (TMR) has been the most frequently studied technique for treating PAP, inhibiting neuroma formation by rerouting the cut mixed nerve to a functional motor nerve. We hypothesise that a primary TMR procedure during major lower limb amputations will result in a lower prevalence of PA</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-05T17:56:51.911Z</modification><creation>2026-05-19T03:11:53.23Z</creation></dates><accession>S-EPMC12587972</accession><cross_references><pubmed>41248411</pubmed><doi>10.1136/bmjopen-2025-105053</doi></cross_references></HashMap>